13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • Vertu

    Acronym: 

    Vertu

    ACTRN/NCT /ethics: 

    ACTRN12615000407594

    Scientific title: 

    A Randomised Phase II study of Veliparib, Radiotherapy and Temozolomide in patients with unmethylated O (6)-methylguanine-DNA methyltransferase (MGMT) Glioblastoma (brain cancer) (VERTU study)

    Summary of trial and patient characteristics

    Cancer Type Brain & central nervous system
    Trial Type Treatment
    Phase Phase II Tumour Stream Brain Cancer
    Age Range 18 years and older Cancer Stage
    Sex Both Anticipated Start Date 2015-12-01
    Molecular Target Anticipated End Date
    Cancer Type Brain & central nervous system
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Brain Cancer
    Cancer Stage
    Anticipated Start Date 2015-12-01
    Anticipated End Date

    Trial Summary

    This study aims to evaluate the safety and effectiveness of a combination of veliparib with radiotherapy, followed by a combination of veliparib with temozolomide (a chemotherapy), to treat patients with newly diagnosed glioblastoma multiforme (a type of brain tumour).

    Lay Summary

    A Randomised Phase II study of Veliparib, Radiotherapy and Temozolomide in patients with unmethylated O (6)-methylguanine-DNA methyltransferase (MGMT) Glioblastoma (brain cancer) (VERTU study)

    Sponsor / Cooperative group

    The University of Sydney

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 7074 2342 Completed